Hope McClaine Cottrill, MD
Clinical Focus
Practice Locations
Education
University of Kentucky College of Medicine
Medical SchoolUniversity of Kentucky College of Medicine
FellowshipUniversity of Southern Florida
ResidencyUniversity Of Kentucky Hospital
Board Certifications
American Board of Obstetrics and Gynecology
American Board of Obstetrics and Gynecology
Hospital Affiliations
- Baptist Health Medical Group
- Baptist Health Lexington
- Baptist Health Louisville
- Baptist Health Richmond
Philosophy of Care
Research
-
Ovarian Carcinoma
CCOO8: A study to compare two surgical procedures in women with BRCA1 mutations to assess reduced risk of ovarian cancer
Trial Details - GOG-3043 Trial Details
- GOG-3078 Gloriosa Trial Details
- GS-US-682-6769 (GOG-3104) Trial Details
-
Low Grade Ovarian Serous Adenocarcinoma
NRG-GY019 -A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Trial Details -
Endometrial Serous Adenocarcinoma (CIRB-22-0046)
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
Learn more at ClinicalTrials.gov.
Trial Details
